Connect your AI

Jade Biosciences, Inc. Common Stock JBIO Q2 2025 earnings

Reported August 13, 2025 · Before market open

Diluted EPS-$0.86Miss by $0.43

EPS estimate-$0.43

Next report

Aug 12, 2026 (in 2 months)

EPS estimate-$0.66

Financials

Q2 2025

Income statement

Operating income-$27.8M-4,608%

Net income-$32.1M-5,346%

EPS (diluted)-$0.86-353%

Balance sheet

Cash & equivalents$220.9M+611%

Total debt$811.0K+19.1%

Total equity$201.6M+20,155,500%

Total assets$224.0M+101%

Cash flow

Operating cash flow-$20.2M—

CapEx$131.0K—

Free cash flow-$20.3M—

Valuation & ratios

Valuation

as of 06/30/25

Market cap$337.83M—

Enterprise value$117.7M—

Returns & leverage

Return on equity-132.5%+120pp

Debt / equity0×-681×

Current ratio10.3×+3.8×

Versus estimates

Diluted EPS

Q1 2026-$0.57Miss by $0.05 Q4 2025-$0.11Beat by $0.34 Q3 2025-$0.48Beat by $0.09

Q2 2025-$0.86Miss by $0.43

Q1 2025-$0.09Beat by $8.31 Q4 2024-$0.19In line

Ask the moment Jade Biosciences, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Harbor at dusk

Questions, answered.

When did Jade Biosciences, Inc. Common Stock report Q2 2025 earnings?: Jade Biosciences, Inc. Common Stock (JBIO) reported Q2 2025 earnings on August 13, 2025 before market open.
What were Jade Biosciences, Inc. Common Stock's Q2 2025 revenue and EPS?: Jade Biosciences, Inc. Common Stock reported diluted EPS of $-0.86 for Q2 2025.
Did Jade Biosciences, Inc. Common Stock beat estimates in Q2 2025?: EPS missed the consensus estimate of $-0.43 by $0.43.
Where can I find Jade Biosciences, Inc. Common Stock's Q2 2025 SEC filings?: You can read the 10-Q periodic report (0001193125-25-179853) directly on SEC EDGAR. The filing index links above go to sec.gov.